Ezetimibe: The First Cholesterol Absorption Inhibitor

P and T

Volumn 28, Issue 3, 2003, Pages

  Domagala, Beata M ^a   Leady, Michelle ^a,b   Streetman, Daniel S ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL ABSORPTION INHIBITOR; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTHRALGIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ABSORPTION; LIVER FUNCTION TEST; MULTICENTER STUDY; MUSCLE FUNCTION; MYOPATHY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 0345564890     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Zetia™ (ezetimibe) package insert. Kenilworth, NJ: Merck/Schering-Plough, October 2002.
2. Sudhop T, Lujohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-1948.
3. Knopp RH, Bays H, Manion CV, et al. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins (Abstract). Atherosclerosis 2001;2(Suppl):90.
4. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-1097.
5. Knopp RH, Gitter H, Truitt, T, et al. Ezetimibe reduces low-density lipoprotein cholesterol: Results of a phase III, randomized, double-blind, placebo-controlled trial (Abstract). Atherosclerosis 2001;2(Suppl):38.
6. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies. Clin Ther 2001;23:1209-1230.
7. Davidson M, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40(12):2125-2134.
8. Ballantyne C, Houri C, Notarbartolo A, et al. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia (Abstract). J Am Coll Cardiol 2002;39(Suppl A):227A.
9. Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-1091.
10. Gagné C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-2475.
11. Von Bergmann K, Salen G, Lutjohann D, et al. Ezetimibe effectively reduces serum plant sterols in patients with sitosterolemia (Abstract). Atherosclerosis 2002;3(2):232.
12. Lee M, Lu K, Patel SB. Genetic basis of sitosterolemia. Curr Opin Lipidol 2001;12:141-149.
13. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
14. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-1107.
15. Altman SW, Davis HR Jr, Yao X, et al. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochem Biophys Acta 2002;1580:77-93.
16. Repa JJ, Dietschy JM, Turley SD. Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in either the intestinal bile acid pool or the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte. J Lipid Res 2002;43:1864-1874.
17. van Heek M, Farley C, Compton DS, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Clin Pharmacol 2001;134:409-417.
18. Ezzet F, Krishna G, Wexler DB, et al. A population pharmaco-kinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001;23:871-875.
19. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Clin Pharmacol 2000;129:1748-1754.
20. Zhu Y, Statkevich P, Kosoglou T, et al. Effect of age on the pharmacokinetics of ezetimibe. American Association of Pharmaceufical Scientists (AAPS) PharmSci Suppl 2000;2:2082.
21. th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.
22. Cohen HE, ed. Red Book. Montvale, NJ: Thomson Medical Economics; 2002.
23. Kosoglou T, Kakkar T, Statkevich P, et al. Multiple-dose safety and pharmacokinetics of eztemibe in adolescent children (Abstract). Clin Pharmacol Ther 2001;69(2):P52.
24. Calder RA. Ezetimibe (Zetia™) data on file (letter). North Wales, PA: Merck/Schering-Plough, January 10, 2003.